2018
DOI: 10.18632/oncotarget.25655
|View full text |Cite
|
Sign up to set email alerts
|

MACROD2 expression predicts response to 5-FU-based chemotherapy in stage III colon cancer

Abstract: BackgroundColorectal cancer (CRC) is caused by genetic aberrations. MACROD2 is commonly involved in somatic focal DNA copy number losses, in more than one-third of CRCs. In this study, we aimed to investigate the association of MACROD2 protein expression with clinical outcome in stage II and stage III colon cancer.MethodsTissue microarrays (TMA) containing formalin-fixed paraffin-embedded tissue cores from 386 clinically well-annotated primary stage II and III colon cancers were stained by immunohistochemistry… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
6
0

Year Published

2018
2018
2022
2022

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 9 publications
(6 citation statements)
references
References 20 publications
0
6
0
Order By: Relevance
“…This nuclear export restricts the time that MACROD2 spend at the DNA lesions, which may decrease the net ADP-ribosylhydrolase activity at these sites of damage (Golia et al, 2017). Low expression of MACROD2 is associated with poor prognosis of colorectal cancer patients (van den Broek et al, 2018). A recent breakthrough report documented the generation of MACROD2 knock-out mice (obtained from the KOMP, Jackson Laboratory), which developed normally into adulthood and displayed significantly enhanced intestinal tumorigenesis in the ApcMin/+ susceptible genetic background (Sakthianandeswaren et al, 2018).…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…This nuclear export restricts the time that MACROD2 spend at the DNA lesions, which may decrease the net ADP-ribosylhydrolase activity at these sites of damage (Golia et al, 2017). Low expression of MACROD2 is associated with poor prognosis of colorectal cancer patients (van den Broek et al, 2018). A recent breakthrough report documented the generation of MACROD2 knock-out mice (obtained from the KOMP, Jackson Laboratory), which developed normally into adulthood and displayed significantly enhanced intestinal tumorigenesis in the ApcMin/+ susceptible genetic background (Sakthianandeswaren et al, 2018).…”
Section: Discussionmentioning
confidence: 99%
“…Heterozygous and homozygous depletion of MACROD2 enhanced significantly intestinal tumorigenesis in this susceptible genetic background (Sakthianandeswaren et al, 2018). Accordingly, at the clinical level, low nuclear expression of MACROD2 is associated with poor prognosis of patients with stage III primary colon cancer (van den Broek et al, 2018).…”
Section: Introductionmentioning
confidence: 99%
“…TMAs have been used in a range of human cancer investigations, including prostate cancer, 15,16 breast cancer, 7 and colon cancer. 8,17,18 The tumor bank within our Comprehensive Cancer Center has been actively collecting FFPE tumor and normal tissues from patients preoperatively consented to IRB-approved tissue procurement protocols to build an FFPE tissue bank to complement our long-standing frozen tissue bank. We have leveraged this resource to generate TMAs for cancer research.…”
Section: Discussionmentioning
confidence: 99%
“…This latter antibody has been discontinued by the company. Despite the poor characterisation of this now retracted MACROD2 antibody, it has for example been used to correlate protein expression to response to chemotherapy in patients with colon cancer 49 . We listed all antibodies available and have found that either no whole blots are shown to demonstrate specificity or that unspecific bands are present ( Supplementary Table S1).…”
Section: Macrod1 Macrod2 and Targ1 Are Differentially Expressed Thementioning
confidence: 99%